Eli Lilly Lietuva - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,406,217 | 1,373,731 | 1,469,099 | 1,554,327 | 1,709,730 | 1,985,636 | 2,280,012 | 2,557,300 |
| Profit before tax | 73,406 | 80,031 | 68,956 | 77,988 | 78,787 | 95,766 | 110,230 | 130,519 |
| Net profit | 59,539 | 62,004 | 55,964 | 63,553 | 63,641 | 75,718 | 88,039 | 101,161 |
| Equity | 1,890,407 | 1,952,411 | 2,008,375 | 2,071,928 | 2,135,569 | 2,211,287 | 2,299,326 | 2,400,486 |
| Liabilities | 16,983 | 40,740 | 44,276 | 24,473 | 32,143 | 59,703 | 75,577 | 23,047 |
| Non-current assets | 17,446 | 36,024 | 39,605 | 34,469 | 44,404 | 32,669 | 39,816 | 46,735 |
| Current assets | 2,019,135 | 2,057,550 | 2,125,073 | 2,211,025 | 2,283,390 | 2,499,099 | 2,704,280 | 2,650,698 |
| Total assets | 2,036,581 | 2,093,574 | 2,164,678 | 2,245,494 | 2,327,794 | 2,531,768 | 2,744,096 | 2,697,433 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 208,065 | 219,666 | 100,703 |
| Social insurance contributions | - | - | - | - | - | 211,481 | 216,780 | 247,403 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -39.4% | -2.3% | +6.9% | +5.8% | +10.0% | +16.1% | +14.8% | +12.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 2.9% | 3.0% | 2.6% | 2.8% | 2.7% | 3.0% | 3.2% | 3.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 3.1% | 3.2% | 2.8% | 3.1% | 3.0% | 3.4% | 3.8% | 4.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.2% | 4.5% | 3.8% | 4.1% | 3.7% | 3.8% | 3.9% | 4.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.2% | 5.8% | 4.7% | 5.0% | 4.6% | 4.8% | 4.8% | 5.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 108,868 | 121,212 | 133,554 | 141,302 | 155,430 | 173,924 | 228,001 | 234,256 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Eli Lilly Lietuva - Social security debts
The company had no debts to Sodra
Eli Lilly Lietuva - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Eli Lilly Lietuva, UAB (code 300089009) is a Private Limited Liability Company engaged in business and other management consultancy activities. In 2025, the company generated revenue of EUR 2.56 million and net profit of EUR 101.2 thousand, compared with EUR 2.28 million revenue and EUR 88.0 thousand net profit in 2024 and EUR 1.99 million revenue and EUR 75.7 thousand net profit in 2023. This shows a steady 2-3 year upward trend in both sales and earnings. Revenue increased by 12.2% year on year in 2025 and by 28.8% over two years, while the profit margin remained stable at 4.0%. The balance sheet remained solid, with total assets of EUR 2.70 million, equity of EUR 2.40 million and liabilities of only EUR 23.0 thousand at the end of 2025. Key ratios also indicate a strong capital structure, including an equity ratio of 89.0%, debt-to-equity of 0.01, ROE of 4.2% and ROA of 3.8%. Revenue per employee was EUR 255.7 thousand in 2025, with profit per employee of EUR 10.1 thousand.